Small-Animal PET Imaging of Amyloid-Beta Plaques with [11C]PiB and Its Multi-Modal Validation in an APP/PS1 Mouse Model of Alzheimer's Disease
暂无分享,去创建一个
Stefan Platzer | Antje Willuweit | Gjermund Henriksen | Alexander Drzezga | Marc Huisman | Markus Schwaiger | Sybille Reder | Frauke Neff | Hans-Jürgen Wester | Behrooz H. Yousefi | A. Drzezga | M. Schwaiger | F. Neff | M. Schoor | Andreas Voss | H. Wester | G. Henriksen | B. Yousefi | M. Huisman | A. Manook | A. Willuweit | S. Platzer | S. Reder | Markus Settles | J. Velden | H. von der Kammer | André Manook | Markus Settles | Andreas Voss | Joachim Velden | Michael Schoor | Heinz von der Kammer | Michael Schoor
[1] A. Drzezga,et al. Metabolically stabilized benzothiazoles for imaging of amyloid plaques. , 2007, Journal of medicinal chemistry.
[2] L. Thurfjell,et al. Phase 1 Study of the Pittsburgh Compound B Derivative 18F-Flutemetamol in Healthy Volunteers and Patients with Probable Alzheimer Disease , 2009, Journal of Nuclear Medicine.
[3] Qinan Bao,et al. Performance Evaluation of the Inveon Dedicated PET Preclinical Tomograph Based on the NEMA NU-4 Standards , 2009, Journal of Nuclear Medicine.
[4] Denise C. Park,et al. Toward defining the preclinical stages of Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease , 2011, Alzheimer's & Dementia.
[5] Ryan Chamberlain,et al. Targeting Vascular Amyloid in Arterioles of Alzheimer Disease Transgenic Mice With Amyloid &bgr; Protein Antibody-Coated Nanoparticles , 2011, Journal of neuropathology and experimental neurology.
[6] Marc Dhenain,et al. Characterization of in vivo MRI detectable thalamic amyloid plaques from APP/PS1 mice , 2009, Neurobiology of Aging.
[7] H. Braak,et al. Neuropathological stageing of Alzheimer-related changes , 2004, Acta Neuropathologica.
[8] R. Buchert,et al. Development of Alzheimer-disease neuroimaging-biomarkers using mouse models with amyloid-precursor protein-transgene expression , 2011, Progress in Neurobiology.
[9] K. Duff,et al. Quantitative histological analysis of amyloid deposition in Alzheimer’s double transgenic mouse brain , 2000, Neuroscience.
[10] H. Kung,et al. Characterization of IMPY as a potential imaging agent for β-amyloid plaques in double transgenic PSAPP mice , 2004, European Journal of Nuclear Medicine and Molecular Imaging.
[11] A. Gee,et al. Evidence for the Presence of Three Distinct Binding Sites for the Thioflavin T Class of Alzheimer's Disease PET Imaging Agents on β-Amyloid Peptide Fibrils* , 2005, Journal of Biological Chemistry.
[12] J. Hardy,et al. Accelerated Alzheimer-type phenotype in transgenic mice carrying both mutant amyloid precursor protein and presenilin 1 transgenes , 1998, Nature Medicine.
[13] Val J Lowe,et al. NEMA NU 2-2007 performance measurements of the Siemens Inveon™ preclinical small animal PET system , 2009, Physics in medicine and biology.
[14] Brian J Bacskai,et al. Four-dimensional multiphoton imaging of brain entry, amyloid binding, and clearance of an amyloid-β ligand in transgenic mice , 2003, Proceedings of the National Academy of Sciences of the United States of America.
[15] J. Morris,et al. The diagnosis of dementia due to Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer's disease , 2011, Alzheimer's & Dementia.
[16] A. Drzezga,et al. Early-Onset and Robust Amyloid Pathology in a New Homozygous Mouse Model of Alzheimer's Disease , 2009, PloS one.
[17] Jeih-San Liow,et al. Linearized Reference Tissue Parametric Imaging Methods: Application to [11C]DASB Positron Emission Tomography Studies of the Serotonin Transporter in Human Brain , 2003, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.
[18] C. Graff,et al. Amyloid imaging in members of a family harbouring the Arctic APP mutation , 2011, Alzheimer's & Dementia.
[19] C. Rowe,et al. Radiation Dosimetry of β-Amyloid Tracers 11C-PiB and 18F-BAY94-9172 , 2009, Journal of Nuclear Medicine.
[20] J. Lamb,et al. Characterisation of the binding of amyloid imaging tracers to rodent Abeta fibrils and rodent-human Abeta co-polymers. , 2006, Biochemical and biophysical research communications.
[21] J. Lamb,et al. Characterisation of the binding of amyloid imaging tracers to rodent Aβ fibrils and rodent-human Aβ co-polymers , 2006 .
[22] S. M. Sumi,et al. The Consortium to Establish a Registry for Alzheimer's Disease (CERAD) , 1991, Neurology.
[23] L. Mucke,et al. Alzheimer-type neuropathology in transgenic mice overexpressing V717F β-amyloid precursor protein , 1995, Nature.
[24] A. Chatziioannou. PET scanners dedicated to molecular imaging of small animal models. , 2002, Molecular imaging and biology : MIB : the official publication of the Academy of Molecular Imaging.
[25] R. Mohs,et al. Consortium to establish a registry for Alzheimer's disease (CERAD) clinical and neuropsychological assessment of Alzheimer's disease. , 2002, Psychopharmacology bulletin.
[26] Tetsuya Suhara,et al. Longitudinal, Quantitative Assessment of Amyloid, Neuroinflammation, and Anti-Amyloid Treatment in a Living Mouse Model of Alzheimer's Disease Enabled by Positron Emission Tomography , 2007, The Journal of Neuroscience.
[27] D. Skovronsky,et al. 18F stilbenes and styrylpyridines for PET imaging of A beta plaques in Alzheimer's disease: a miniperspective. , 2010, Journal of medicinal chemistry.
[28] K. Blennow,et al. Characterization of the Brain β-Amyloid Isoform Pattern at Different Ages of Tg2576 Mice , 2011, Neurodegenerative Diseases.
[29] C Vollmar,et al. Quantitative comparison of automatic and interactive methods for MRI-SPECT image registration of the brain based on 3-dimensional calculation of error. , 2000, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[30] Kazuhiko Yanai,et al. 2-(2-[2-Dimethylaminothiazol-5-yl]Ethenyl)-6- (2-[Fluoro]Ethoxy)Benzoxazole: A Novel PET Agent for In Vivo Detection of Dense Amyloid Plaques in Alzheimer's Disease Patients , 2007, Journal of Nuclear Medicine.
[31] S. DeKosky,et al. Binding of the Positron Emission Tomography Tracer Pittsburgh Compound-B Reflects the Amount of Amyloid-β in Alzheimer's Disease Brain But Not in Transgenic Mouse Brain , 2005, The Journal of Neuroscience.
[32] Anat Biegon,et al. Serial microPET measures of the metabolic reaction to a microdialysis probe implant , 2006, Journal of Neuroscience Methods.
[33] S. Siegel,et al. Performance evaluation of the microPET focus: a third-generation microPET scanner dedicated to animal imaging. , 2005, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[34] R. P. Maguire,et al. Consensus Nomenclature for in vivo Imaging of Reversibly Binding Radioligands , 2007, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.
[35] R. Vandenberghe,et al. Whole-Body Biodistribution and Radiation Dosimetry of 18F-GE067: A Radioligand for In Vivo Brain Amyloid Imaging , 2009, Journal of Nuclear Medicine.
[36] G Blomqvist,et al. Comparison of the Transient Equilibrium and Continuous Infusion Method for Quantitative PET Analysis of [11C]Raclopride Binding , 1998, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.
[37] Allan R. Jones,et al. The Allen Brain Atlas: 5 years and beyond , 2009, Nature Reviews Neuroscience.
[38] Martin Gotthardt,et al. Spatial Resolution and Sensitivity of the Inveon Small-Animal PET Scanner , 2008, Journal of Nuclear Medicine.
[39] W. Klunk,et al. Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound‐B , 2004, Annals of neurology.
[40] George Paxinos,et al. The Mouse Brain in Stereotaxic Coordinates , 2001 .
[41] M. Mattson,et al. Triple-Transgenic Model of Alzheimer's Disease with Plaques and Tangles Intracellular Aβ and Synaptic Dysfunction , 2003, Neuron.
[42] V. Libri,et al. Interaction of the amyloid imaging tracer FDDNP with hallmark Alzheimer’s disease pathologies , 2009, Journal of neurochemistry.
[43] W. Klunk,et al. Synthesis and evaluation of 11C-labeled 6-substituted 2-arylbenzothiazoles as amyloid imaging agents. , 2003, Journal of medicinal chemistry.
[44] Tyler E. Benedum,et al. Preclinical Properties of 18F-AV-45: A PET Agent for Aβ Plaques in the Brain , 2009, Journal of Nuclear Medicine.
[45] James Robert Brašić,et al. In Vivo Imaging of Amyloid Deposition in Alzheimer Disease Using the Radioligand 18F-AV-45 (Flobetapir F 18) , 2010, Journal of Nuclear Medicine.
[46] Clifford R. Jack,et al. Regional differences in MRI detection of amyloid plaques in AD transgenic mouse brain , 2011, NeuroImage.
[47] Ciprian Catana,et al. Small-Animal Molecular Imaging Methods , 2010, Journal of Nuclear Medicine.
[48] Jerry Sedgewick,et al. Scientific Imaging with Photoshop: Methods, Measurement, and Output , 2008 .
[49] I. M. Klotz. Numbers of receptor sites from Scatchard graphs: facts and fantasies. , 1982, Science.
[50] T. Pugsley,et al. A rapid filtration assay for soluble receptors using polyethylenimine-treated filters. , 1983, Analytical biochemistry.
[51] Nelleke Tolboom,et al. Simplified parametric methods for [11C]PIB studies , 2008, NeuroImage.
[52] M. Hüll,et al. Dual-Biomarker Imaging of Regional Cerebral Amyloid Load and Neuronal Activity in Dementia with PET and 11C-Labeled Pittsburgh Compound B , 2011, The Journal of Nuclear Medicine.
[53] G. Schellenberg,et al. Clinical and neuropathological features of the arctic APP gene mutation causing early-onset Alzheimer disease. , 2008, Archives of neurology.
[54] D. Borchelt,et al. Accelerated Amyloid Deposition in the Brains of Transgenic Mice Coexpressing Mutant Presenilin 1 and Amyloid Precursor Proteins , 1997, Neuron.
[55] M. Pontecorvo,et al. The use of the exploratory IND in the evaluation and development of 18F-PET radiopharmaceuticals for amyloid imaging in the brain: a review of one company's experience. , 2009, The quarterly journal of nuclear medicine and molecular imaging : official publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology (IAR), [and] Section of the Society of....
[56] B. Långström,et al. The use of PET in Alzheimer disease , 2010, Nature Reviews Neurology.
[57] A. Drzezga,et al. Synthesis and evaluation of 11C-labeled imidazo[2,1-b]benzothiazoles (IBTs) as PET tracers for imaging β-amyloid plaques in Alzheimer's disease. , 2011, Journal of medicinal chemistry.
[58] M. Mintun,et al. A quantitative model for the in vivo assessment of drug binding sites with positron emission tomography , 1984, Annals of neurology.
[59] Markus Rudin,et al. In vivo detection of amyloid-β deposits by near-infrared imaging using an oxazine-derivative probe , 2005, Nature Biotechnology.
[60] C. Kuntner,et al. Limitations of Small Animal PET Imaging with [18F]FDDNP and FDG for Quantitative Studies in a Transgenic Mouse Model of Alzheimer’s Disease , 2009, Molecular Imaging and Biology.
[61] Z. Khachaturian. Revised criteria for diagnosis of Alzheimer’s disease: National Institute on Aging-Alzheimer's Association diagnostic guidelines for Alzheimer's disease , 2011, Alzheimer's & Dementia.
[62] K. Zahs,et al. Probing the Biology of Alzheimer's Disease in Mice , 2010, Neuron.
[63] V. Libri,et al. PIB is a non-specific imaging marker of amyloid-beta (Abeta) peptide-related cerebral amyloidosis. , 2007, Brain : a journal of neurology.
[64] D. Dickson,et al. Amyloid Phenotype Characterization of Transgenic Mice Overexpressing both Mutant Amyloid Precursor Protein and Mutant Presenilin 1 Transgenes , 1999, Neurobiology of Disease.
[65] Michael V. Green,et al. PET imaging of brain with the β-amyloid probe, [11C]6-OH-BTA-1, in a transgenic mouse model of Alzheimer’s disease , 2005, European Journal of Nuclear Medicine and Molecular Imaging.
[66] Hartwig Wolburg,et al. Aβ42‐driven cerebral amyloidosis in transgenic mice reveals early and robust pathology , 2006, EMBO reports.
[67] M. Albert,et al. Introduction to the recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease , 2011, Alzheimer's & Dementia.
[68] Martin Eichner,et al. Long-Term In Vivo Imaging of β-Amyloid Plaque Appearance and Growth in a Mouse Model of Cerebral β-Amyloidosis , 2011, The Journal of Neuroscience.
[69] Doris J. Doudet,et al. Animal Models of Neurodegenerative Disease: Insights from In vivo Imaging Studies , 2007, Molecular Imaging and Biology.
[70] B. Sommer,et al. Two amyloid precursor protein transgenic mouse models with Alzheimer disease-like pathology. , 1997, Proceedings of the National Academy of Sciences of the United States of America.
[71] M. Citron,et al. Strategies for disease modification in Alzheimer's disease , 2004, Nature Reviews Neuroscience.
[72] S. Younkin,et al. Correlative Memory Deficits, Aβ Elevation, and Amyloid Plaques in Transgenic Mice , 1996, Science.
[73] William E. Klunk,et al. The Binding of 2-(4′-Methylaminophenyl)Benzothiazole to Postmortem Brain Homogenates Is Dominated by the Amyloid Component , 2003, The Journal of Neuroscience.
[74] S. DeKosky,et al. Simplified quantification of Pittsburgh Compound B amyloid imaging PET studies: a comparative analysis. , 2005, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[75] H. Kung,et al. F-18 stilbenes as PET imaging agents for detecting beta-amyloid plaques in the brain. , 2005, Journal of medicinal chemistry.
[76] A. Drzezga,et al. A Novel (18)F-Labeled Imidazo[2,1-b]benzothiazole (IBT) for High-Contrast PET Imaging of β-Amyloid Plaques. , 2011, ACS medicinal chemistry letters.